Sector News

Juno Therapeutics soars on report of Celgene deal talks

January 18, 2018
Life sciences

Juno Therapeutics shares soared more than 50 percent in premarket trading after The Wall Street Journal reported the biotech company is in talks to be acquired by Celgene.

Shares of Juno rose $26.71 to $72.31 in premarket trading on Wednesday morning. The Seattle-based company had a market share of about $5.2 billion as of Tuesday.

Celgene is seeking to broaden its portfolio of blood-cancer drugs before Revlimid, its top-selling drug, loses its patent protection, The Journal noted. Juno’s approach is focused on developing treatments that use the body’s immune system to fight cancer.

The acquisition discussions could result in a deal within weeks, although it’s unclear how much Celgene would pay for Juno, The Journal added.

Source: CBS News

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend